Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Receivables - Accured (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Receivables - Accured data on record, last reported at $2.2 million in Q3 2025.

  • For Q3 2025, Receivables - Accured fell 34.83% year-over-year to $2.2 million; the TTM value through Sep 2025 reached $2.2 million, down 34.83%, while the annual FY2024 figure was $2.9 million, 11.81% down from the prior year.
  • Receivables - Accured reached $2.2 million in Q3 2025 per ZNTL's latest filing, down from $2.5 million in the prior quarter.
  • Across five years, Receivables - Accured topped out at $3.3 million in Q4 2023 and bottomed at $266000.0 in Q1 2022.
  • Average Receivables - Accured over 4 years is $1.9 million, with a median of $2.2 million recorded in 2025.
  • Peak YoY movement for Receivables - Accured: surged 719.48% in 2024, then crashed 34.83% in 2025.
  • A 4-year view of Receivables - Accured shows it stood at $508000.0 in 2022, then surged by 556.89% to $3.3 million in 2023, then dropped by 11.81% to $2.9 million in 2024, then fell by 26.81% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Accured were $2.2 million in Q3 2025, $2.5 million in Q2 2025, and $2.7 million in Q1 2025.